The Diagnostic Revolution: Data, Speed, and the Future of Patient Care

ANAHEIM, CA – July 27, 2026 – The future of medicine is unfolding here at the Association for Diagnostics & Laboratory Medicine (ADLM) Conference, and it is being written in a language of speed, precision, and data. At the forefront of this shift is Thermo Fisher Scientific, the global leader in serving science, which is leveraging the conference to unveil a suite of diagnostic tools that promise to transform patient care by tackling some of healthcare’s most persistent and complex challenges.

The company’s strategy hinges on a simple yet profound observation articulated by Puneet Sarin, senior vice president and president of specialty diagnostics at Thermo Fisher: “the traditional boundaries between research, translational medicine and diagnostics continue to blur.” This philosophy is embodied in a portfolio designed to arm clinicians with faster, more accurate results, moving from a reactive model of medicine to one that is predictive and proactive.

Accelerating the Pace of Precision Oncology

For patients facing a potential cancer diagnosis, the wait for definitive results is an agonizing period of uncertainty. Thermo Fisher is directly addressing this critical window with two major innovations. The first is the newly FDA-cleared EXENT® Solution, a fully automated mass spectrometry platform poised to revolutionize the diagnosis of multiple myeloma. This blood cancer, which affects over 176,000 people worldwide each year, has traditionally been diagnosed using methods like serum protein electrophoresis that can be slow, labor-intensive, and highly dependent on subjective interpretation. The EXENT system replaces this ambiguity with the precision of mass spectrometry, detecting the tell-tale M-proteins with a sensitivity that can enable earlier, more confident diagnoses. By automating the workflow, it not only improves accuracy but also frees up highly skilled laboratory professionals, a critical advantage amid widespread staffing shortages.

Equally impactful is the Oncomine™ Dx Express Test (ODxET). For patients with non–small cell lung cancer (NSCLC), genomic information is the key to unlocking life-saving targeted therapies. Yet, conventional next-generation sequencing (NGS) can take several weeks—a dangerously long time for a rapidly progressing disease. The ODxET, running on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, shatters this timeline. By delivering comprehensive genomic results in as little as 24 hours, it allows care teams to act on critical information almost immediately. This rapid turnaround can mean the difference between promptly starting an effective targeted therapy, like sunvozertinib for patients with specific EGFR mutations, and enduring a prolonged diagnostic journey while the disease advances.

Bringing Clarity to Complex Chronic Conditions

Beyond oncology, Thermo Fisher is applying its integrated approach to notoriously difficult-to-diagnose chronic illnesses. The company's new EliA™ CTD 13 Screen, which received FDA 510(k) clearance in June 2026, offers a lifeline for patients suffering from systemic autoimmune connective tissue diseases (CTDs) like lupus and Sjögren’s syndrome. These conditions are infamous for their vague, overlapping symptoms, often leading to a long and frustrating diagnostic odyssey. The EliA screen streamlines this process by combining a screen for 13 relevant antigens into a single, automated assay. This provides clinicians with objective, standardized results that can guide more targeted follow-up testing, bringing much-needed clarity to complex cases and helping patients get answers sooner.

This focus on unmet needs is perhaps most evident in the company's work in maternal health. Preeclampsia, a dangerous hypertensive disorder, affects up to 8% of pregnancies globally and remains a leading cause of maternal and neonatal death. The Thermo Scientific PreClara Ratio™, the first FDA-cleared biomarker test for preeclampsia risk assessment, provides a crucial tool for managing this threat. By measuring the ratio of two key placental biomarkers, the test helps clinicians identify pregnant women at high risk of progressing to severe preeclampsia, enabling closer monitoring and timely intervention. In a field where clinical signs can be ambiguous, this objective data point has the power to save lives.

The Digital Backbone: Reshaping the Modern Laboratory

Underpinning these advanced assays and instruments is a sophisticated digital strategy designed to address the immense operational pressures facing modern laboratories. As testing volumes grow and workflows become more complex, efficiency and quality control become paramount. Thermo Fisher’s LabLink360™ software tackles this head-on, creating a centralized digital hub for quality management. By using Sigma-metric analysis for global benchmarking, labs can assess their performance, optimize quality control protocols, and even reduce the burden of routine QC tasks without compromising accuracy. Paired with automated controls, this system allows technicians to shift their focus from compliance paperwork to what matters most: delivering fast, reliable patient results.

This digital integration extends across the portfolio, from the B·R·A·H·M·S Fast Screen™ PLUS software that standardizes prenatal screening workflows to the end-to-end support Thermo Fisher provides to other diagnostic companies. By offering its manufacturing, regulatory, and co-development expertise, the company is not just a provider of products but a foundational partner in the broader diagnostic ecosystem. This holistic approach, which connects advanced research instruments like the TSQ Certis™ Mass Spectrometer with scalable clinical platforms and robust digital oversight, demonstrates a clear vision for the future of diagnostics—one that is seamlessly integrated from the research bench to the patient’s bedside.